Naccache, Jean-Marc
Montil, Melissa
Cadranel, Jacques
Cachanado, Marine
Cottin, Vincent
Crestani, Bruno
Valeyre, Dominique
Wallaert, Benoit
Simon, Tabassome
Nunes, Hilario
Funding for this research was provided by:
Roche (RAF15.014- P140908-VAL 2015-245)
PHRC (PHRC 2014-P140908 – AOM14502)
Article History
Received: 21 October 2018
Accepted: 10 March 2019
First Online: 11 April 2019
Ethics approval and consent to participate
: This study received approval from the French ethics committee (Comité de protection des personnes Ile de France X, Hôpital Robert Balanger) as well as from the National French Drug Safety Agency (EudraCT: 2015–000492-27). The French Ministry of Health (DGOS) has designated experts’ committee for reviewing the protocol.Informed written consent will be obtained by the investigator from research participant prior to inclusion in the study. If it is not possible for the person solicited to consent in writing, the consent is certified by a third party. This third party must have no connection with the investigator or the administration manager. A materials consent will be obtained to specifically address the collection of the DAN and RNA biobank (see above: Biological sample collection). Model consent form and other related documentation given to participants and authorised surrogates.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.